Drugs / Mefloquine
Mefloquine
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | LARIAM | — | 1992-11-23 | fda.gov ↗ |
| Approved | US (FDA) | LARIAM | — | 1989-05-02 | fda.gov ↗ |
Trials 29 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 23 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02524444 Comparator | Sep 2015 → Aug 2016 | — | ORIYOMI OMOTOYOSI AKINYOTU | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02488980 Comparator | May → Oct 2000 | Plasmodium falciparum malaria | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT04847661 Comparator | Mar 2021 → Jun 2022 | COVID-19 | Helwan University | Completed | No outcome recorded |
| Phase 2/3 | NCT02453308 Comparator | Aug 2015 → Mar 2018 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 2/3 | NCT00936767 Comparator | Oct 2010 | Plasmodium falciparum malaria | University of Oxford | Withdrawn | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT03939104 Comparator | Jun 2021 → Jan 2023 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT03923725 Comparator | Sep 2020 → Mar 2024 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT03452475 Comparator | Mar 2018 → Jun 2019 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT01939886 Comparator | Apr → Nov 2013 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT02974348 Comparator | Jan → May 2013 | Plasmodium falciparum malaria | University of Bamenda | Completed | No outcome recorded |
| Phase 3 | NCT01708876 Comparator | Oct 2012 → Dec 2014 | — | Menzies School of Health Research | Completed | No outcome recorded |
| Phase 3 | NCT00970879 Comparator | Dec 2009 → Jul 2012 | HIV infectious disease, malaria | Research Institute for Development | Completed | No outcome recorded |
| Phase 3 | NCT00403260 Comparator | Jan 2007 → Oct 2008 | Plasmodium falciparum malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 3 | NCT00373607 Comparator | Jul 2003 → Jul 2005 | malaria | Institute of Tropical Medicine, Belgium | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT02653898 Comparator | Jan → Aug 2016 | malaria | Armed Forces Research Institute of Medical Sciences, Thailand | Unknown | No outcome recorded |
| Phase 4 | NCT01976780 Comparator | Jun 2013 → Dec 2014 | Plasmodium falciparum malaria | Global Emerging Infections Surveillance and Response System | Completed | No outcome recorded |
| Phase 4 | NCT00902811 Comparator | Dec 2008 → Oct 2009 | Plasmodium falciparum malaria | Medecins Sans Frontieres, Netherlands | Unknown | No outcome recorded |
| Phase 4 | NCT00444106 Comparator | May 2007 → Nov 2008 | Plasmodium falciparum malaria | Novartis | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT03813108 Background | Apr 2019 → Feb 2021 | Plasmodium falciparum malaria | Radboud University Medical Center | Terminated | No outcome recorded |
| — | NCT01640587 Comparator | Nov 2013 → Mar 2017 | Plasmodium falciparum malaria | University of Oxford | Terminated | No outcome recorded |
| — | NCT00499876 Comparator | Oct 2007 → Oct 2008 | HIV infectious disease, malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| — | NCT01659281 Comparator | Sep 2007 → May 2008 | Plasmodium falciparum malaria | Armed Forces Research Institute of Medical Sciences, Thailand | Completed | No outcome recorded |
| — | NCT00493363 Comparator | Jun 2007 → Dec 2009 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 53 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mefloquine | “Artesunate-mefloquine fixed dose combination (artesunate 25mg/mefloquine hydrochloride 55mg, or artesunate 100mg/mefloquine hydrochloride 220mg), according to age-group.” NCT00902811 ↗51“Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes while taking mefloquine prophylaxis.” NCT03813108 ↗ “THN201: Donepezil 5mg capsule and Mefloquine 10mg capsule once daily for 15 days” NCT03698695 ↗ “Mefloquine 250 mg tablet, single dose” NCT01615822 ↗ “Mefloquine hydrochloride for 3 days” NCT02453308 ↗ |
| Known as | Eloquine | “One tablet of mefloquine contains 250 mg mefloquine (Eloquine® (Medochemie Ltd., Cyprus)” NCT01640587 ↗ |
| Known as | mefloquine hydrochloride | “Adults with fever, a positive peripheral blood smear, and a positive rapid diagnostic test for Plasmodium falciparum were randomised in both studies to either azithromycin (AZ)...” PMID 25425434 ↗ Nov 20141“Mefloquine hydrochloride will be given in a dose of 1100-1650 mg, according to body weight (BW), splitted into two to three doses.” NCT04847661 ↗ |
| Route | Oral | “Oral administration of mefloquine can induce vomiting in children suffering from clinical malaria.” NCT00158574 ↗ |